| Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (NCT02677948) | University of Michigan Rogel Cancer Center | 2016-10-01 |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma (NCT02819583) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2016-10-01 |
| Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) (NCT02910583) | Pharmacyclics LLC. | 2016-09-28 |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients (NCT02877082) | Emory University | 2016-09-01 |
| Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas (NCT02891590) | Zhejiang DTRM Biopharma | 2016-09-01 |
| Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery (NCT02767388) | University of Nebraska | 2016-09-01 |
| Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas (NCT02900716) | Zhejiang DTRM Biopharma | 2016-09-01 |
| Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects (NCT02825836) | Telios Pharma, Inc. | 2016-08-26 |
| Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia (NCT02756897) | M.D. Anderson Cancer Center | 2016-07-07 |
| A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) (NCT02801578) | M.D. Anderson Cancer Center | 2016-07-06 |
| Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma (NCT02851589) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2016-07-01 |
| A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor (NCT02640833) | AbbVie | 2016-07-01 |
| A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) (NCT02756611) | AbbVie | 2016-06-22 |
| Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia (NCT02827617) | Oncology Institute of Southern Switzerland | 2016-06-01 |
| Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL (NCT02784834) | Michael Choi | 2016-06-01 |
| Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. (NCT02611908) | Michael Choi | 2016-06-01 |
| Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma (NCT02339922) | University of Washington | 2016-05-19 |
| A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia (NCT02619604) | Duke University | 2016-05-01 |
| Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy (NCT02742090) | TG Therapeutics, Inc. | 2016-04-21 |
| Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia (NCT02629809) | M.D. Anderson Cancer Center | 2016-03-18 |
| A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (NCT02717611) | Acerta Pharma BV | 2016-03-08 |
| Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program (NCT02582320) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2016-03-01 |
| Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) (NCT02669017) | ADC Therapeutics S.A. | 2016-03-01 |
| Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO) (NCT02689141) | German CLL Study Group | 2016-02-04 |
| Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia (NCT02491398) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2016-02-01 |
| Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies (NCT03076437) | Shenzhen Institute for Innovation and Translational Medicine | 2016-01-15 |
| Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT02518555) | Jennifer Woyach | 2016-01-12 |
| A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 (NCT02656303) | TG Therapeutics, Inc. | 2016-01-07 |
| Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant (NCT02506933) | City of Hope Medical Center | 2015-12-21 |
| Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia (NCT02530515) | M.D. Anderson Cancer Center | 2015-12-18 |
| A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL (NCT02514083) | National Heart, Lung, and Blood Institute (NHLBI) | 2015-12-09 |
| A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT02537613) | Dana-Farber Cancer Institute | 2015-12-01 |
| Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies (NCT02556931) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-12-01 |
| Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia (NCT02612311) | TG Therapeutics, Inc. | 2015-11-19 |
| Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL (NCT02557516) | Innate Pharma | 2015-11-09 |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis (NCT02593123) | Virginia Commonwealth University | 2015-11-04 |
| Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab (NCT02993536) | Abramson Cancer Center at Penn Medicine | 2015-11-01 |
| Reduced Intensity Conditioning Transplant Using Haploidentical Donors (NCT02581007) | Northside Hospital, Inc. | 2015-10-26 |
| Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency (NCT02553447) | University of Nebraska | 2015-10-19 |
| Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation (NCT02535286) | TG Therapeutics, Inc. | 2015-09-18 |
| Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies (NCT02507479) | Sheba Medical Center | 2015-09-01 |
| Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. (NCT02315768) | University of California, San Diego | 2015-08-26 |
| Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia (NCT02427451) | Kerry Rogers | 2015-08-03 |
| Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) (NCT02477696) | Acerta Pharma BV | 2015-07-28 |
| Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL (NCT02475681) | Acerta Pharma BV | 2015-06-26 |
| Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients (NCT02481297) | M.D. Anderson Cancer Center | 2015-06-23 |
| CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma (NCT02424968) | Robert Lowsky | 2015-06-01 |
| Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (NCT02396134) | City of Hope Medical Center | 2015-05-21 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors (NCT02440685) | Asana BioSciences | 2015-05-01 |
| Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia (NCT02340780) | Canadian Cancer Trials Group | 2015-04-27 |
| Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia (NCT01980875) | Gilead Sciences | 2015-04-21 |
| Economic Analysis of Alliance A041202 CLL Study (NCT02414022) | Canadian Cancer Trials Group | 2015-04-15 |
| Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies (NCT02456350) | Shenzhen Second People's Hospital | 2015-04-01 |
| A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (NCT02320487) | Genentech, Inc. | 2015-03-31 |
| Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) (NCT02301156) | TG Therapeutics, Inc. | 2015-01-27 |
| Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL (NCT02337829) | Acerta Pharma BV | 2015-01-12 |
| Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies (NCT02290951) | Regeneron Pharmaceuticals | 2015-01-09 |
| Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma (NCT02258555) | Gilead Sciences | 2015-01-01 |
| Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia (NCT02144623) | Lund University Hospital | 2015-01-01 |
| Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia (NCT02316197) | Merck KGaA, Darmstadt, Germany | 2014-12-31 |
| Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL (NCT02296918) | Acerta Pharma BV | 2014-12-22 |
| Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02129582) | Case Comprehensive Cancer Center | 2014-11-05 |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant (NCT01930162) | Novartis Pharmaceuticals | 2014-10-07 |
| A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (NCT02264574) | Pharmacyclics LLC. | 2014-10-06 |
| Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT (NCT02294552) | Ivan S Moiseev | 2014-10-01 |
| A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (NCT02251548) | Dana-Farber Cancer Institute | 2014-10-01 |
| Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) (NCT02242045) | Gilead Sciences | 2014-10-01 |
| A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia (NCT01739491) | Janssen Pharmaceutica | 2014-10-01 |
| Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members (NCT02194387) | M.D. Anderson Cancer Center | 2014-09-17 |
| A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy (NCT02141282) | AbbVie | 2014-09-10 |
| Occupational Status and Hematological Disease (NCT02057185) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2014-09-08 |
| Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections (NCT02231853) | National Heart, Lung, and Blood Institute (NHLBI) | 2014-09-03 |
| Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia (NCT02131584) | M.D. Anderson Cancer Center | 2014-09-02 |
| Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection (NCT02109224) | National Cancer Institute (NCI) | 2014-09-01 |
| Observational Study in CLL Patients Receiving BR (NCT02381899) | Czech CLL Study Group | 2014-09-01 |
| Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia (NCT02157324) | Acerta Pharma BV | 2014-08-18 |
| UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT02222688) | Thomas Kipps | 2014-08-08 |
| Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) (NCT02208037) | National Heart, Lung, and Blood Institute (NHLBI) | 2014-08-01 |
| Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention (NCT01951885) | Case Comprehensive Cancer Center | 2014-07-07 |
| A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL (NCT02158091) | Dana-Farber Cancer Institute | 2014-06-27 |
| An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia (NCT02080884) | Hoffmann-La Roche | 2014-06-24 |
| A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL (NCT02135133) | Dana-Farber Cancer Institute | 2014-06-01 |
| Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression (NCT02863718) | German CLL Study Group | 2014-04-30 |
| Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) (NCT02200848) | Georgetown University | 2014-04-01 |
| Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia (NCT02015208) | Sunnybrook Health Sciences Centre | 2014-04-01 |
| A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (NCT02005471) | Hoffmann-La Roche | 2014-03-17 |
| TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (NCT02100852) | TG Therapeutics, Inc. | 2014-03-12 |
| Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT02048813) | National Cancer Institute (NCI) | 2014-03-10 |
| Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia (NCT01980888) | Gilead Sciences | 2014-02-05 |
| Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) (NCT02046928) | Ångstrom Pharmaceuticals | 2014-02-01 |
| Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (NCT01853631) | Baylor College of Medicine | 2014-02-01 |
| ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia (NCT02029443) | Acerta Pharma BV | 2014-01-30 |
| A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL) (NCT01671904) | Genentech, Inc. | 2014-01-13 |
| T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies (NCT01163201) | Masonic Cancer Center, University of Minnesota | 2014-01-01 |
| Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies (NCT02006485) | TG Therapeutics, Inc. | 2013-12-13 |
| Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia (NCT03847727) | Pirogov Russian National Research Medical University | 2013-12-03 |
| A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 (NCT02049515) | SecuraBio | 2013-12-01 |
| Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (NCT01634217) | Masonic Cancer Center, University of Minnesota | 2013-11-08 |
| A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia (NCT01905943) | Hoffmann-La Roche | 2013-11-04 |
| A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) (NCT02004522) | SecuraBio | 2013-11-01 |